Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00034879 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00034879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00034879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2000
Completion date
October 31, 2003
Enrollment
Not reported
Sites
626

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, metastases, neoplasm, non-small-cell lung